14:33:47 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
RaySearch Laboratories är verksamma inom medicinteknik. Bolaget är specialiserade inom utveckling av mjukvarulösningar för sjukvårdsindustrin. Särskilt område där bolagets produkter används är inom cancervården. Bolagets produkter vidaresäljs som dosplanerings- respektive informationssystem. Olika funktioner inkluderar maskininlärning, beräkningshastighet, automatiserad planering, virtuell simulering, adaptiv terapi och digitala arbetsflöden. Produkterna används av ett flertal kliniker.

Kalender

2022-05-25 Årsstämma 2022
2022-05-18 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning RAY B 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning RAY B 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-22 Ordinarie utdelning RAY B 0.00 SEK
2019-05-21 Årsstämma 2019
2019-05-09 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning RAY B 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning RAY B 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Ordinarie utdelning RAY B 0.25 SEK
2016-05-17 Årsstämma 2016
2016-05-12 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning RAY B 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-08 Kvartalsrapport 2015-Q1
2015-02-12 Bokslutskommuniké 2014
2014-11-27 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning RAY B 0.00 SEK
2014-05-27 Årsstämma 2014
2014-05-16 Kvartalsrapport 2014-Q1
2014-02-13 Bokslutskommuniké 2013
2013-11-27 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning RAY B 0.00 SEK
2013-05-22 Årsstämma 2013
2013-05-16 Kvartalsrapport 2013-Q1
2013-02-14 Bokslutskommuniké 2012
2012-11-16 Kvartalsrapport 2012-Q3
2012-08-28 Kvartalsrapport 2012-Q2
2012-05-31 Ordinarie utdelning RAY B 0.00 SEK
2012-05-30 Årsstämma 2012
2012-05-23 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-11-24 Kvartalsrapport 2011-Q3
2011-05-26 Ordinarie utdelning RAY B 0.50 SEK
2011-05-25 Årsstämma 2011
2011-05-04 Kvartalsrapport 2011-Q1
2011-02-18 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-27 Kvartalsrapport 2010-Q2
2010-05-26 Ordinarie utdelning RAY B 0.50 SEK
2010-05-25 Årsstämma 2010
2010-05-11 Kvartalsrapport 2010-Q1
2009-11-20 Kvartalsrapport 2009-Q3
2009-08-27 Kvartalsrapport 2009-Q2
2009-05-27 Ordinarie utdelning RAY B 0.00 SEK
2009-05-26 Årsstämma 1
2009-05-15 Kvartalsrapport 2009-Q1
2008-06-25 Split RAY B 1:3
2003-06-10 Split RAY B 20:1
2021-11-18 07:45:00

"In the third quarter of 2021, license revenue rose 37 percent and support revenue rose 12 percent. Overall, net sales rose 15 percent and operating loss totaled SEK -27 M (-29)", says Johan Löf, CEO of RaySearch.

THIRD QUARTER (JULY-SEPTEMBER 2021)
  • Order intake SEK 127.9 M (138.5)
  • Net sales SEK 136.4 M (119.1)
  • Operating loss SEK -26.6 M (-29.5)
  • Loss after tax SEK -22.0 M (-26.2)
  • Loss per share before/after dilution SEK -0.64 (-0.76)
  • Cash flow SEK -10.1 M (pos: 21.7)
  • Order backlog SEK 1,211.6 M (1,228.5) at the end of the period
FIRST NINE MONTHS (JANUARY-SEPTEMBER 2021)
  • Order intake SEK 462.7 M (615.6)
  • Net sales SEK 453.1 M (491.8)
  • Operating loss SEK -36.8 M (profit: 11.1)
  • Loss after tax SEK -31.3 M (profit: 5.1)
  • Loss per share before/after dilution SEK -0.91 (earnings: 0.15)
  • Cash flow SEK -51.6 M (pos: 83.4)
SIGNIFICANT EVENTS DURING THE THIRD QUARTER
  • The RayStation® treatment planning system was sold to more leading cancer centers, including National Cancer Centre Singapore (NCCS), Centro de Tratamiento e Investigación sobre cáncer Luis Carlos Sarmiento Angulo (CTIC) in Colombia, and Queen Elizabeth Hospital (QEH) in Hong Kong. In addition, Iridium Network in Belgium expanded its existing RayStation installation.
  • In September, Iridium Network in Belgium, one of RaySearch's development partners for RayCare, decided to invest in RayCare as its primary oncology information system.
  • In September, RayStation was taken into clinical use together with Accuray's CyberKnife therapy device at Centre hospitalier universitaire vaudois (CHUV) in Switzerland.
THE COVID-19 PANDEMIC
  • The COVID-19 pandemic with temporary reorganizations in healthcare also had a negative impact on sales in the third quarter. RaySearch expects that the negative effects of the COVID-19 pandemic on the company's sales and earnings will continue for some months to come, mainly because orders may be delayed.
SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD
  • In October, RayCare was taken into clinical use with Accuray's Radixact® treatment delivery system at Swiss Medical Network in Switzerland.
  • RaySearch and IBA are expanding their collaboration around proton therapy in the areas of FLASH radiotherapy, proton arc therapy and the treatment of tumors in motion.  
  • RaySearch and Mevion Medical Systems are expanding their collaboration on the development of treatment planning methods for FLASH radiotherapy with the Mevion S250i Proton Therapy System.
  • When access is granted to the new head office premises in the fourth quarter of 2021, total assets are expected to increase approximately SEK 466 M in accordance with IFRS 16.
  • Torbjörn Wingårdh was appointed new CFO of RaySearch as of November 15, 2021.

TELECONFERENCE IN CONJUNCTION WITH THE INTERIM REPORT

CEO Johan Löf and CFO Peter Thysell will present RaySearch's interim report for January-September 2021 at a teleconference to be held in English on Thursday, November 18, 2021 at 10:00-10:30 a.m. CET.

For login details to the teleconference, please register on:
http://emea.directeventreg.com/registration/5435207

FOR FURTHER INFORMATION, PLEASE CONTACT:

Johan Löf, President and CEO                   Tel: +46 8 510 530 00              E-mail: johan.lof@raysearchlabs.com
Peter Thysell, CFO                                     Tel: +46 70 661 05 59              E-mail: peter.thysell@raysearchlabs.com

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on November 18, 2021 at 7:45 a.m. CET.

ABOUT RAYSEARCH

RaySearch is a medical technology company that develops innovative software solutions to improve cancer care. The company markets worldwide its treatment planning system RayStation[®] and next-generation oncology information system RayCare[®]*. The latest additions to RaySearch's product line are RayIntelligence[®] and RayCommand[®]. RayIntelligence is an oncology analysis system (OAS) that cancer clinics can use to collect, structure and analyze data. The treatment control system (TCS) RayCommand[®] is designed as a link between the treatment machine and the systems for dose planning and oncology information. RaySearch software is used in about 2,600 clinics in over 65 countries. The company was founded in 2000 and the share has been listed on Nasdaq Stockholm since 2003. More information about RaySearch is available at www.raysearchlabs.com.

* Subject to regulatory clearance in some markets.